Investors & Media

Press Releases

Press Releases

Date Title View
February 28, 2024 Sage Therapeutics to Present at Upcoming March Investor Conferences
February 14, 2024 Sage Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Highlights Pipeline and Business Progress
January 31, 2024 Dalzanemdor (SAGE-718) Awarded Innovation Passport Designation for Cognitive Impairment Associated with Huntington’s Disease and Entry into the Innovative Licensing and Access Pathway by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA)
January 31, 2024 Sage Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 14, 2024
January 8, 2024 Sage Therapeutics to Provide Business Updates at 42nd Annual J.P. Morgan Healthcare Conference
January 8, 2024 Sage Therapeutics Announces Changes to Board of Directors
January 2, 2024 Sage Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024